BUPROPION

Search structure
Synonyms:
Status: Approved (1985)
Entry Type: Small molecule
Molecule Category: Parent
ATC: N06AX12
UNII: 01ZG3TPX31

Structure
InChI Key SNPPWIUOZRMYNY-UHFFFAOYSA-N
Smile CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
InChI
InChI=1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3

Physicochemical Descriptors

Property Name Value
Molecular Formula C13H18ClNO
Molecular Weight 239.75
AlogP 3.3
Hydrogen Bond Acceptor 2.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 3.0
Polar Surface Area 29.1
Molecular species NEUTRAL
Aromatic Rings 1.0
Heavy Atoms 16.0

Pharmacology

Primary Target
DAT
NET
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Cytochrome P450 Cytochrome P450 family 2 Cytochrome P450 family 2C Cytochrome P450 2C19
- 1998.3 - - -
Enzyme Hydrolase
- - - -
Ion channel Ligand-gated ion channel Nicotinic acetylcholine receptor Nicotinic acetylcholine receptor alpha subunit
- 12-12000 - - -
Ion channel Ligand-gated ion channel Nicotinic acetylcholine receptor Nicotinic acetylcholine receptor beta subunit
- 12-12000 - - -
Ion channel Ligand-gated ion channel Nicotinic acetylcholine receptor Nicotinic acetylcholine receptor delta subunit
- 7.9-7900 - - -
Ion channel Ligand-gated ion channel Nicotinic acetylcholine receptor Nicotinic acetylcholine receptor gamma subunit
- 7.9-7900 - - -
Ion channel Voltage-gated ion channel Potassium channels Voltage-gated potassium channel
- 69000 - - -
Membrane receptor
- 1800 - - -
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC06 neurotransmitter transporter family
- 330-2900 - 173-871 61.5
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides
- - - - 7.2-108.53

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Depressive Disorder 4 D003866 ClinicalTrials
Depressive Disorder, Major 4 D003865 ClinicalTrials
Depressive Disorder, Major 4 D003865 ClinicalTrials
Schizophrenia 3 D012559 ClinicalTrials
Depressive Disorder, Treatment-Resistant 3 D061218 ClinicalTrials
Smoking Cessation 3 D016540 ClinicalTrials
Obesity 3 D009765 ClinicalTrials
Anxiety 3 D001007 ClinicalTrials
Dementia 3 D003704 ClinicalTrials
Tobacco Use Disorder 3 D014029 ClinicalTrials
Attention Deficit Disorder with Hyperactivity 3 D001289 ClinicalTrials
Crohn Disease 2 D003424 ClinicalTrials
Marijuana Abuse 2 D002189 ClinicalTrials
Huntington Disease 2 D006816 ClinicalTrials
Restless Legs Syndrome 2 D012148 ClinicalTrials
Cocaine-Related Disorders 2 D019970 ClinicalTrials
Substance-Related Disorders 2 D019966 ClinicalTrials
Substance-Related Disorders 2 D019966 ClinicalTrials
Alcoholism 2 D000437 ClinicalTrials
Amphetamine-Related Disorders 2 D019969 ClinicalTrials
Anemia, Sickle Cell 1 D000755 ClinicalTrials
Neoplasms 1 D009369 ClinicalTrials
Carcinoma, Non-Small-Cell Lung 1 D002289 ClinicalTrials
Sexual Dysfunction, Physiological 1 D012735 ClinicalTrials
Head and Neck Neoplasms 1 D006258 ClinicalTrials
Melanoma 1 D008545 ClinicalTrials
Prostatic Neoplasms, Castration-Resistant 1 D064129 ClinicalTrials
Alzheimer Disease 1 D000544 ClinicalTrials
Diabetes Mellitus, Type 2 1 D003924 ClinicalTrials
Mitochondrial Diseases 1 D028361 ClinicalTrials
Bipolar Disorder 1 D001714 ClinicalTrials
Leukemia, Lymphocytic, Chronic, B-Cell 1 D015451 ClinicalTrials

Related Entries

Salt
Parent

Cross References

Resources Reference
CAS NUMBER 34911-55-2
ChEBI 3219
ChEMBL CHEMBL894
DrugBank DB01156
DrugCentral 435
EPA CompTox DTXSID7022706
FDA SRS 01ZG3TPX31
Human Metabolome Database HMDB0001510
Guide to Pharmacology 7135
KEGG C06860
PharmGKB PA448687
PubChem 444
SureChEMBL SCHEMBL38777
CONTENTS